Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Commentary|Articles|February 13, 2026
Non-Chemo, Biomarker-Driven Perioperative Strategies Highlight Bladder Cancer Presentations to Watch at ASCO GU 2026
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan
Bladder cancer experts share the most anticipated abstracts expected at the 2026 Genitourinary Cancers Symposium.
Advertisement
Advertisement
With the
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Advertisement
Advertisement